Aerogen

Executive Summary

Aerogen is a privately held Irish medical device company, headquartered in Galway, specializing in aerosol drug delivery systems for respiratory therapy. Founded in 1997, the company has established itself as a leader in vibrating mesh nebulizer technology, enabling precise and efficient delivery of inhaled medications across both ventilated and non-ventilated patients. Its products are used in critical care, emergency care, and other hospital settings, facilitating respiratory therapies at every stage of patient care. Aerogen's technology is designed to enhance drug deposition, reduce waste, and improve clinical outcomes, positioning the company as a key partner for pharmaceutical companies developing inhaled therapies. Despite a lack of public financial data, Aerogen's sustained presence in the market and strong clinical reputation suggest a robust competitive position in the growing respiratory drug delivery sector. The company's focus on innovation and strategic collaborations likely underpins its ongoing growth, though visibility into its operations remains limited due to its private status.

Upcoming Catalysts (preview)

• Q2 2026FDA 510(k) Clearance for Next-Generation Nebulizer Platform80% success
• Q4 2026Pharmaceutical Partnership for Inhaled Biologic Delivery60% success
• Q1 2027Expansion into Asia-Pacific Acute Care Markets70% success